Evidence supporting the use of: Immunoglobulin
For the health condition: Staph Infections

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Immunoglobulin (specifically, intravenous immunoglobulin or IVIG) has been explored as an adjunctive therapy for severe Staphylococcus aureus infections, particularly in cases of toxic shock syndrome and certain cases of severe, refractory infections. The scientific rationale is that IVIG preparations contain a broad spectrum of antibodies, including some that may neutralize staphylococcal toxins and enhance opsonization of the bacteria, potentially improving outcomes in patients who are not responding to standard antibiotic therapy.

However, the evidence supporting IVIG use in Staph infections is limited and mixed. Some small clinical trials and case reports have suggested benefits, especially in toxin-mediated disease, but larger randomized controlled trials have not consistently demonstrated a clear advantage. Systematic reviews (e.g., by the Cochrane Collaboration and others) have concluded that there is insufficient high-quality evidence to recommend routine IVIG use for Staphylococcus aureus infections.

Most guidelines do not recommend IVIG as a standard treatment for Staph infections but do acknowledge its potential role in selected severe cases, such as streptococcal or staphylococcal toxic shock syndrome, where it may be considered on a case-by-case basis. In summary, while there is some scientific rationale and limited evidence for IVIG use in specific severe Staph infection scenarios, its use is not broadly validated or standard, and the overall strength of evidence is modest.

More about immunoglobulin
More about Staph Infections

Products containing immunoglobulin

We currently have no products on Vitabase that contain this ingredient.